AZ | RU | EN
Avita Azərbaycan Karyera Məhsullarımız Partnyorlarımız
İnfeksion xəstəliklər / Sultam

guideline.gov

Guideline Title

Pelvic inflammatory disease. In: Sexually transmitted diseases treatment guidelines, 2010.

Bibliographic Source(s)

Centers for Disease Control and Prevention (CDC). Pelvic inflammatory disease. In: Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010 Dec 17;59(RR-12):63-7.

Guideline Status

This is the current release of the guideline.

This guideline updates a previous version: Centers for Disease Control and Prevention. Pelvic inflammatory disease. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2006 Aug 4;55(RR-11):56-61.

http://guideline.gov/content.aspx?id=25586&search=ampicillin+sulbactam

 

 

 

Guideline Title

Best practice policy statement on urological surgery antimicrobial prophylaxis.

Bibliographic Source(s)

American Urological Association Education and Research, Inc. Best practice policy statement on urologic surgery antimicrobial prophylaxis. Baltimore (MD): American Urological Association Education and Research, Inc.; 2007. 45 p. [100 references]

Guideline Status

This is the current release of the guideline.

http://guideline.gov/content.aspx?id=12210&search=ampicillin+sulbactam

Infect Dis Obstet Gynecol. 1997; 5(5): 319-325.

doi:  10.1155/S1064744997000562

PMCID: PMC2364580

 

 

 

Copyright © 1997 Hindawi Publishing Corporation.

Ampicillin/Sulbactam Vs. Cefoxitin for the Treatment of Pelvic Inflammatory Disease

Joseph G. Jemsek 1,2 and Frank Harrison1

1 Department of Obstetrics and Gynecology, Charlotte Memorial Hospital, Charlotte, NC, USA,

2 Nalle Clinic, 1918 Randolph Road, Charlotte, NC, 28207, USA,

Corresponding author.

Received December 27, 1996; Accepted October 28, 1997.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective: The safety and efficacy of ampicillin plus sulbactam were compared with those of cefoxitin in the treatment of women with pelvic inflammatory disease (PID).

Methods: This single-site, randomized, prospective, third-party-blinded, comparative, parallel-treatment study enrolled 93 women with a diagnosis of PID. Patients were treated with either ampicillin/sulbactam (2 g/1 g, administered intravenously [IV], every 6 h) or cefoxitin (2 g, administered IV, every 6 h) for a minimum of 12 doses. Patients with cultures positive for Chlamydia trachomatis also received concurrent oral or IV doxycycline (100 mg twice daily). Patients with cultures negative for C. trachomatis received prophylactic oral doxycycline (100 mg twice daily) for 10-14 days after treatment with either ampicillin/sulbactam or cefoxitin was completed.

Results: Ninety-three patients were entered in the study: 47 in the ampicillin/sulbactam arm and 46 in the cefoxitin arm. All 93 patients were evaluable for safety; 61 (66%) were evaluable for efficacy. Demographic characteristics were similar for the groups. Of the 27 evaluable ampicillin/sulbactam-treated patients, 67% experienced clinical cure, 30% improved, and 4% failed treatment. Respective values for the 34 cefoxitin-treated patients were 68%, 24%, and 9% (P = 0.67). Pathogens were eradicated in 70% of the women given ampicillin/sulbactam vs. 56% of those who received cefoxitin (P = 0.64).

Conclusions: Overall, ampicillin/sulbactam demonstrated clinical and bacteriologic efficacy at least equivalent to that of cefoxitin in the treatment of women with acute PID. The use of ampicillin/sulbactam for this indication may avoid the complex dosing regimens associated with other treatments.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364580/

ClinicalTrials.gov

Comparison of Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Intrapartum Chorioamnionitis: a Randomized Controlled Trial

This study is currently recruiting participants.

Verified January 2012 by Stanford University

First Received on April 7, 2009.   Last Updated on January 11, 2012

http://clinicaltrials.gov/ct2/show/NCT00879190

 

Ampicillin/Sulbactam versus Cefuroxime as antimicrobial prophylaxis for cesarean delivery: a randomized study

Eleftherios Ziogos1Sotirios Tsiodras2Ioannis Matalliotakis1Helen Giamarellou2and Kyriaki Kanellakopoulou2*

  • *Corresponding author: Kyriaki Kanellakopouloukyrkanel@yahoo.gr
  • † Equal contributors

Author Affiliations

1Department of Obtsterics and Gynecology, University General Hospital of Heraclion, Heracleion, Greece

24th Academic Department of Internal Medicine, University of Athens Medical School, Athens, Greece

For all author emails, please log on.

BMC Infectious Diseases 2010, 10:341 doi:10.1186/1471-2334-10-341

The electronic version of this article is the complete one and can be found online at:

http://www.biomedcentral.com/1471-2334/10/341

 

Received:

14 April 2010

Accepted:

30 November 2010

Published:

30 November 2010


© 2010 Ziogos et al; licensee BioMed Central Ltd. 

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

The efficacy and safety of a single dose of ampicillin/sulbactam compared to a single dose of cefuroxime at cord clamp for prevention of post-cesarean infectious morbidity has not been assessed.

Methods

Women scheduled for cesarean delivery were randomized to receive a single dose of either 3 g of ampicillin-sulbactam or 1.5 g of cefuroxime intravenously, after umbilical cord clamping. An evaluation for development of postoperative infections and risk factor analysis was performed.

Results

One hundred and seventy-six patients (median age 28 yrs, IQR: 24-32) were enrolled in the study during the period July 2004 - July 2005. Eighty-five (48.3%) received cefuroxime prophylaxis and 91 (51.7%) ampicillin/sulbactam. Postoperative infection developed in 5 of 86 (5.9%) patients that received cefuroxime compared to 8 of 91 (8.8%) patients that received ampicillin/sulbactam (p = 0.6). In univariate analyses 6 or more vaginal examinations prior to the operation (p = 0.004), membrane rupture for more than 6 hours (p = 0.08) and blood loss greater than 500 ml (p = 0.018) were associated with developing a postoperative surgical site infection (SSI). In logistic regression having 6 or more vaginal examinations was the most significant risk factor for a postoperative SSI (OR 6.8, 95% CI: 1.4-33.4, p = 0.019). Regular prenatal follow-up was associated with a protective effect (OR 0.04, 95% CI: 0.005-0.36, p = 0.004).

Conclusions

Ampicillin/sulbactam was as safe and effective as cefuroxime when administered for the prevention of infections following cesarean delivery.

http://www.biomedcentral.com/1471-2334/10/341

Xəbərlər
Xəbər Arxivi
Milli və Beynəlxalq Konfransların Anonsu
Copyright © 2012. AVITA! Bütün hüquqlar qorunur. Sayt  Lider veb studiyası  tərəfindən hazırlanmışdır